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T cell-specific inactivation of mouse 
CD2 by CRISPR/Cas9
Jane Beil-Wagner1,2, Georg Dössinger1, Kilian Schober1, Johannes vom Berg2, Achim Tresch3,4, 
Martina Grandl1, Pushpalatha Palle2, Florian Mair5, Markus Gerhard1, Burkhard Becher5, 
Dirk H. Busch1 & Thorsten Buch1,2
The CRISPR/Cas9 system can be used to mutate target sequences by introduction of double-strand 
breaks followed by imprecise repair. To test its use for conditional gene editing we generated mice 
transgenic for CD4 promoter-driven Cas9 combined with guide RNA targeting CD2. We found that 
within CD4+ and CD8+ lymphocytes from lymph nodes and spleen 1% and 0.6% were not expressing 
CD2, respectively. T cells lacking CD2 carryied mutations, which confirmed that Cas9 driven by cell-type 
specific promoters can edit genes in the mouse and may thus allow targeted studies of gene function in 
vivo.
Genome modification in the mouse has become an essential research tool for addressing gene function in vivo. 
Since 1987, targeted mutagenesis in the mouse has been performed by manipulating embryonic stem (ES) cells 
in vitro1. Chimeric mice that were partially derived from these ES cells were used to find new, manipulated mouse 
lines. As an extension to this technology, recombinases such as Cre are used to avoid the use of resistance genes, 
to allow embryonic-lethal mutations and to make inducible, cell-type specific knockouts and knock-ins2–4. While, 
recombinase-mediated conditional gene targeting has drastically widened the scope of the technology, it still 
relies on ES cells for introduction of the recombinase targets such as loxP sites. Further, mouse lines carrying a 
loxP-containing allele need to be intercrossed with a Cre transgene to address target gene function. Altogether, 
the minimal time for generation of such conditional mutants is more than a year. Recently, a paradigm shift 
in germline mutagenesis has taken place through DNA editing by designer nucleases. Zinc finger nucleases, 
Tal effector nucleases, and the CRISPR/Cas9 system have facilitated the generation of gene-modified animals 
without the use of ES cells5–9. These designer nucleases can be tailored to introduce single- or double-strand 
breaks into target genes, which are repaired through cell-intrinsic repair mechanisms. Non-homologous end 
joining-mediated repair leads to insertions or deletions10 and homologous recombination in the presence of 
a donor fragment facilitates introduction of defined mutations11. In the mouse, designer nuclease-mediated 
mutagenesis is achieved through injection of nuclease-encoding plasmids, RNA or protein into zygotes followed 
by screening of the founder animals5,6. Recently, the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) in combination with CRISPR associated gene 9 (Cas9) system has surpassed the other designer nucle-
ases in terms of efficiency and flexibility. It has proven to allow both insertions/deletions and specific targeted 
mutagenesis in the germline of the mouse8,12–14 and in human cells14,15. The original CRISPR/Cas9 system from 
Streptococcus pyogenes16 was modified for application in molecular biology and now relies on a single 102 bp long 
guide RNA (gRNA), of which 20 bp determine the target sequence17. Since, the exact choice of gRNA is subject to 
further restrictions, such as presence of the Protospacer Adjacent Motif (PAM) sequence (NGG) and uniqueness 
within the target genome, online tools have been developed for designing functionally competent gRNAs18,19. 
The CRSIPR/Cas9 system has been used to modify genes in the germline by transient expression in the zygote 
and was found to facilitate somatic mutations in the mouse when expression of the system was under control of 
the Cre/loxP system and gRNA was delivered through viruses or transfection20. Only recently, it was shown in 
mice that doxycycline-induced Cas9 allows conditional in vivo gene editing21. In Drosophila melanogaster, Cas9 
was shown to enable efficient cell-specific gene editing after its placement under a tissue-specific promoter22. 
However, direct gRNA/Cas9-mediated conditional gene editing using cell-type specific promoters similar to con-
ditional mutagenesis by Cre has been so far not reported for the mouse (Fig. 1a). Such an approach would allow 
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single-step analysis of gene function within a cell lineage circumventing tedious gene targeting and crossing 
necessary for Cre/loxP-mediated conditional gene ablation.
To test whether gRNA/Cas9 could drive cell-type specific mutagenesis in the mouse, we placed Cas9 under 
control of a CD4 promoter (CD4dsCas9), thus initiating the expression in T lymphocytes during their matura-
tion in the thymus (Fig. 1b)23. In a second construct, we placed a gRNA expression cassette under control of a 
U6 promoter (U6gRNA(CD2)). The gRNA was directed against a target sequence in exon 2 of CD2 (Fig. 1b), 
an easily detectable surface marker found on all T cells. In addition, we chose this target because its deficiency 
does not influence cell viability24 and does not lead to changes in the cell’s phenotype, that could impair this 
proof of concept study. The two constructs were co-injected into the pronuclei of oocytes of FVB/N mice and 
offspring were screened for presence of the transgenes. Two transgenic founders carrying both constructs were 
identified (Fig. 1c). We also obtained two founders carrying solely the Cas9 and two carrying solely the gRNA 
construct (data not shown). Further analysis of peripheral blood by flow cytometry revealed that in one of the 
double-transgenic founders a fraction of CD4+ (0.4%) and CD8+ (0.5%) cells lacked expression of CD2 (Fig. 2). 
No such populations were found in wildtype controls (data not shown), the other double-transgenic (Suppl. Fig. 1) 
or Cas9 and gRNA single-transgenic founders (Fig. 2). Furthermore, we analyzed pooled lymph nodes and spleen 
cells of two double transgenic F1 mice as well as of two wildtype littermates to verify the initial blood analysis. 
Here we observed that 1% of CD4+ and 0.6% of CD8+ T cells were not expressing CD2 anymore (Fig. 3). A 
transgene copy number analysis by real-time PCR was performed for this transgenic line and indicated num-
bers of integrated Cas9 being 26 and 41 and of the gRNA of 12 and 6/7 (Fig. 4a). In addition, CD4-Cas9 mRNA 
expression was found solely in T cells and thymocytes but not B cells of double transgenic (dTG) mice or wildtype 
thymocytes (Fig. 4b). U6-driven gRNA(CD2.0) expression was detected in total spleen and thymus of dTGs but 
not in WT controls (Fig. 4c). To confirm that the CD2 locus was edited by gRNA/Cas9, we single cell-sorted T 
cells lacking CD2 and sequenced a fragment around the target site after single cell PCR amplification and cloning 
(Fig. 5a). We observed that eight out of the nine sequenced CD2−CD4+ T cells carried a mutation in the amplicon 
(Fig. 5b). In CD2−CD8+ T cells two of the three amplicons were wildtype and one mutated (Fig. 5b). In all ampli-
cons, we only found a single sequence, either mutated or wildtype. This may be either result of a technical bias 
leading to amplification of only one allele or alternatively an outcome of repair of the second allele by homologous 
Figure 1. Conditional gene editing. (a) Scheme of the concept of conditional gene editing. In the Cas9 driver 
strain, the nuclease is placed under control of a cell type or lineage specific promoter. The gRNA construct 
is driven by the ubiquitous U6 promoter. Both transgenes are co-injected into oocytes. In double-transgenic 
animals, cell-type specific gene deletions are induced. (b) Scheme of constructs used for the CD4dsCas9/
U6gRNA(CD2) mouse strain. The two used linearized plasmids are shown. First, distal and proximal enhancer, 
CD4 promoter followed by exon 1, part of exon 2 and Cas9 with a PolyA at the end. Second, the U6 promoter 
driven gRNA specific for CD2 followed by the U6 terminator (U6 T). (c) PCR analysis of tail biopsies for 
presence of CD4dsCas9 (835 bp amplicon) (lanes 1 and 5) and U6gRNA(CD2.0) (407 bp amplicon) (lanes 1 
and 5) by PCR. DNA from a wildtype (WT) mouse as well as H20 were run as a negative control. 2, 3 and 4 were 
non-transgenic litter mates.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:21377 | DOI: 10.1038/srep21377
recombination using an already mutated donor allele. In all 17 amplicons from CD2+ T cells as well as nine 
amplicons from CD19+ B cells, we obtained solely unmutated sequences (Fig. 5b). As an additional control, we 
performed single cell PCR on FVB/N wildtype CD4+ and CD8+ T cells and sequenced the PCR products, again 
yielding solely wildtype sequences (Fig. 5b). Sequence analysis of the mutations found within the amplicons from 
Figure 2. Abrogation of CD2 expression on a small population of peripheral blood T cells. Analysis of 
blood lymphocytes of the indicated transgenic mice by flow cytometry. Shown are live cells within a lymphocyte 
gate. CD4 and CD8 cells are additionally gated on TCRβ . The percentages of cells found within the marked gates 
of the dot plot analysis are shown.
Figure 3. Abrogation of CD2 expression on a small population of lymph node/splenic T cells. Flow 
cytometric analysis of pooled lymphocytes from lymph nodes and spleens of two double transgenic and 
wildtype mice. Shown are live cells within a lymphocyte gate. The four plots on the right are additionally gated 
on TCRβ + cells. The percentages of cells found within the marked gates of the dot plot analysis are indicated.
www.nature.com/scientificreports/
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CD2− T cells revealed deletions spanning up to 19 bp and insertions of one to four base pairs, five were found as 
out of frame and one in frame (Fig. 5c). Two mutations were repeatedly found (Fig. 5c).
Even though we observed CD2− T cells in a gRNA/Cas9 double-transgenic situation, we were surprised that 
the number of these cells was extremely low. This may have been a specific result of this particular founder due 
to expression variegation or may constitute a general problem of the approach. We therefore analyzed the T cell 
compartments in our different transgenic mice in greater detail. The ratio of CD4+ TCRβ + and CD8+ TCRβ + 
T to CD19+ B cells was found to be slightly increased in double-transgenic (8 (CD4+ TCRβ +) and 2.2 (CD8+ 
TCRβ +)) versus Cas9 single (4.8 (CD4+ TCRβ +) and 1.4 (CD8+ TCRβ +)) and gRNA transgenic animals (4.9 
(CD4+ TCRβ +) and 1.8 (CD8+ TCRβ +)), thus ruling out a general counter-selection of CD4+ and CD8+ T cells. 
Since expression of nucleases such as Cre recombinase were reported to lead to apoptosis in situations of high 
proliferative activity25 and also for Cas9 toxic in vivo effects were described22, we analyzed CD4+ and CD8+ T cells 
for cell death (Suppl. Fig. 2a,b). We obtained no evidence of an increased number of dead cells in lymphocytes of 
the gRNA/Cas9 double-transgenic situation compared to Cas9 or gRNA single transgenic mice as well as wildtype 
mice. Thus, in our model we cannot find evidence for genotoxicity of gRNA and Cas9. Another important point 
regarding the use of CRISPR/Cas9 for in vivo and ex vivo use are off-target effects. Whereas some groups report 
high specificity of CRISPR/Cas926,27 others show high frequency of off-target effects28,29. Several groups found 
that off-target effects can be reduced by the use of optimized gRNAs28,30,31. In our case off-target effects were not 
analyzed because our on-target frequency of modification was already low32.
Taken together, our data indicate that gRNA/Cas9 can be used to mutate target genes in specific cell lineages 
in the mouse. The frequency of such mutations in our system was low. We excluded that this was result of the 
actual gene deficiency by using a target whose absence was shown to have no effect over T cell survival24. Also, 
we did not find evidence that nuclease activity would increase cell death and thereby remove the edited cells 
from the population, which could explain the low frequency of mutations. One reason for inefficient abrogation 
of CD2 expression may, of course, be a feature of this particular transgenic founder. Defined and characterized 
Cas9-driver lines that are crossed to gRNA lines may overcome such problems in the future. To address this point 
we analyzed gRNA expression and Cas9 expression on mRNA and protein level. gRNA was expressed in both 
spleen and thymus. However, while we clearly detected Cas9 mRNA, we failed to see expression of the protein 
(0.25 ng Cas9 protein detection limit, data not shown). Thus, low protein expression levels in our particular 
founder line may contribute to the low efficiency of the system. To further address whether or not the efficiency 
of the used gRNA contributed to the observed low mutation frequencies we compared by in vitro digestion of 
a PCR product the used gRNA (gRNA(CD2.0) to three other gRNAs (gRNA(CD2.1,CD2.2,CD2.3)) targeting 
the same region (Fig. 6). We found that gRNA(CD2.1) showed almost no cutting and gRNA(CD2.2) complete 
digest. The gRNA(CD2.0) used for generating the transgenic mice presented with good but not complete cutting 
Figure 4. Analysis of transgene copy numbers and mRNA expression levels. (a) Serial dilutions of genomic 
DNA from three F1 offspring of founder #5 (Fig. 1c) were analyzed by real-time PCR specific for sequences 
within the indicated (trans)genes. A regression analysis was performed to calculate the copy number of the 
transgenes in each individual mouse, as indicated in the table. (b) Relative expression of CD4-Cas9 transgenic 
and endogenous CD4 mRNA. Transgenic splenic B cells, T cells and thymocytes as well as wildtype thymocytes 
were magnetically enriched and analyzed by RT-PCR. The CD4-Cas9 product is spanning the intron between 
CD4 Exon 1 and Cas9 ORF. Cxxc1 and Ywhaz served as housekeeping gene. Data was normalized to “dTG 
T cells Spleen”. (c) Relative expression of gRNA(CD2.0). Splenocytes and thymocytes of three different dTG 
offspring as well as of a wildtype control were analyzed by RT-PCR. Cxxc1 and Ywhaz served as housekeeping 
gene. Data was normalized to “dTG Thymus” of the third offspring.
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efficiency, along with gRNA(CD2.3) (Fig. 6). It thus appears unlikely that the low in vivo efficiency of CD4-Cas9/
gRNA(CD2.0) is sole result of suboptimal gRNA performance. Methylation of target loci as factor contributing 
to efficiency of Cas9-mediated genome editing has been also discussed and assessed, though with contradictory 
results18,32, but chromatin structure in general appears to influence Cas9 binding32,33. Interestingly, Cre-induced 
Cas9 expression from within the gt(ROSA)26Sor locus combined with viral gRNA expression also resulted 
in only infrequent gene editing in 0.1% to 1.8% of lung cells20 while a recent report of doxycycline-regulated 
Cas9-mediated gene editing showed significantly higher frequencies of mutated cells21. gRNA library transduc-
tion experiments in EL4 cells, a mouse thymic cell line, was found to also lead to only 0.94–3.60% mutant cells 
when analyzing different surface markers34. Furthermore, we were not able to efficiently mutate CD2 in T cell 
transfection experiments (data not shown). While certainly the evidence is still anecdotal, T cells may be difficult 
to modify by CRISPR/Cas9. One way to increase the frequency of gene editing events leading to inactivation 
of gene functionality may be the use of multiple gRNAs towards the same target. Yet, even in such an approach 
only 2/3 of alleles will carry an out-of-frame mutation. CRISPR/Cas9-mediated in vivo targeted mutagenesis 
may thus work best when a critical region, such as an enzymatic site, is functionally compromised even through 
in-frame in/del mutations. Nevertheless, also in the here-described simple version conditional DNA editing is 
extremely useful. It allows rapid assessment of cell-type specific phenotypic changes in a time frame incomparable 
to classical conditional mutagenesis, especially when mutant cells can be easily identified for phenotypic analysis. 
Additionally, for the investigation of onco- and tumor suppressor genes the observed low editing frequency may 
prove to be advantageous. Taken together, this proof of concept study shows that direct conditional gene editing 
by gRNA/Cas9 transgenesis may extend the toolbox for genetic studies in the mouse.
Methods
Methods were carried out in accordance with the approved guidelines.
Animal Models. hCas9 (a gift from George Church (Addgene plasmid # 41815))15 was PCR-amplified 
and placed into the second exon of CD4 in a construct (CD4-DEPE, gift from Marc Schmidt-Supprian) con-
sisting of the CD4 promoter, the distal and the proximal enhancer, exon 1 and parts of exon 2 but lacking the 
intronic silencer, thus supporting expression in all α β T cells. Subsequently, the plasmid was digested with 
NotI. The Crispr design tool at crispr.mit.edu was used to identify the protospacer specific for CD2 Exon 2 
(5′ -GACTAGGCTGGAGAAGGACC-3′ ), which was cloned via BbsI into a modified px330 vector (px330ccd-
BChR), thus replacing a ccdB/chloramphenicol cassette. The transgene was cut out by BciVI and XbaI. Both 
Figure 5. Single cell PCR analysis of the target region within the CD2 locus. Peripheral blood lymphocytes 
were surface stained for CD2, CD4, CD8, TCRβ and CD19 and the following populations within live cell and 
lymphocyte gates single cell-sorted by flow cytometry: TCRβ + CD4+ CD2+, TCRβ + CD8+ CD2+, TCRβ + 
CD4+ CD2−, TCRβ + CD8+ CD2−, CD19+. A 253 bp long region including the gRNA target was amplified by 
two rounds of nested PCR. Products were cloned in pGEM-T and pGEM-Teasy and sequenced. For wildtype 
controls the single cell PCR products were column-purified and sequenced directly. (a) Agarose gel showing 
PCR products of single cell amplicons of the target region within the CD2 gene locus from sorted peripheral 
blood single cells. Lanes 6 and 12 on both sides of the marker are H20 negative controls. (b) Table showing 
the number of obtained mutations in amplicons of double-transgenic and wildtype cells. (c) Alignment of the 
obtained sequences from the CD2 gene amplicon. Indicated is the number (left side) and the cell type as well as 
the outcome of the mutation (OF: out of frame, IF: in frame) (right side) of the respective sequence. – indicates a 
deletion and red bases insertions.
www.nature.com/scientificreports/
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constructs were injected into FVB/N oocytes. The founders were screened by PCR using the following primers: 
CD4 Cas9 typ fwd: 5′ - tgc tca caa ccc ttt agt tt-3′ , CD4 Cas9 typ rev: 5′ -ctt ttt atc ctc ctc cac c-3′ (product length: 
835bp); U6 fwd: 5′ -gag ggc cta ttt ccc atg att cc-3′ , T7 gRNA rev: 5′ -gca cgc gct aaa aac gga-3′ (product length: 
407bp). Animals were kept in barrier-SPF level animal facilities at Technische Universität München according to 
German Animal Protection Law. Experiments were conducted under the license number 55.2-1-54-2532-2-12 
and approved by the Regierung von Oberbayern.
Transgene copy number determination. We estimated genomic transgene abundance by performing 
a RT-PCR using SsoFast EvaGreen (BioRad) with following primers: Cas9F2: 5′ -aag aga acc cga tca acg a-3′ , 
Cas9R2: 5′ -aga tta cca aac agg ccg t-3′ ; Cas9F3: 5′ -gcg cta ggc tgt cca aat-3′ , Cas9R3: 5′ -att taa agt tgg ggg tca gcc-
3′ ; gRNA(CD2.0)F2: 5′ -tgg aaa gga cga aac acc ga-3′ , gRNA(CD2.0)R2: 5′ -cac gcg cta aaa acg gac-3′ ; CD8aFb: 
5′ -caa gga agc aag tgg tat gaa-3′ , CD8aRb: 5′ -ttt cca gat tta ccg tac cg-3′ ; TCRaF: 5′ -tcc ggc caa acc atc tgt-3′ and 
TCRaR: 5′ -cgc tgg ggg aga tga cta t-3′ . A linear regression was performed, in which the dependent variable, the 
(decadic) logarithm of the amount of DNA used in each PCR experiment was explained by the mean Ct-value 
(number of PCR cycles until detection level) in replicate experiments and gene-specific primer pairs were used.
. ( ) +~1 log Quantity of genomic DNA Ct Gene10 value
Here, “Ct value” is a continuous variable, and “Gene” is a nominal variable with 5 distinct values coding for 
the 5 primer pairs used (“CD8a”,“TCRa”,“gRNA CD2.0”,“Cas9 2”,“Cas9 3”). As a result, we obtain one coefficient 
for “Ctvalue”, β Cvalue, and 5 coefficients for “Gene”, β CD8a, β TCRa, β gRNA(CD2.0) , β Cas9_2, β Cas9_3 (one of the latter 5 is 
redundant and set to zero. For our purpose, it is irrelevant which one is chosen). As a result, we obtain a regres-
sion line for each primer pair (see plots Fig. 1d). The difference in the coefficients for each factor level of “Gene” 
is the log10 of the fold difference in genomic abundance of the corresponding amplicons (genes). We chose, the 
mean 2. γ = ( β CD8a + β TCRa)/2 of the coefficients β CD8a and β TCRa as reference value, corresponding to two genomic 
copies of an amplicon. The genomic abundance of gRNA CD2.0 was then estimated as 3. 2*10^(γ -β TCRa) (the 
factor 2 accounts for the two copies of the reference genes), and the genomic abundance of Cas9 was estimated 
Figure 6. Functional analysis (a) In vitro test of gRNA efficiency. gRNA(CD2.0) as well as three controls 
(CD2.1,CD2.2, CD2.3) were incubated with a PCR product for the indicated period of time. Digests were 
separated on an agarose gel. (b) Analysis of the gRNA efficiency. The intensities of the bands resulting from 
gRNA/Cas9-digested PCR product of three different experiments were analyzed using ImageJ. Shown is the 
mean and standard error of the mean.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:21377 | DOI: 10.1038/srep21377
as 4. 2*10^(γ – (β Cas9_2 + β Cas9_3)/2). In the latter case, we averaged the two abundance measurements for Cas9. 
Calculations were carried out in R (Version 3.2.0)35.
RT-PCR. The determination of CD4-Cas9 expression was performed on MACS-isolated B and T cells using 
mouse CD19 microbeads and mouse Pan T Cell Isolation Kit II according to manufacturer’s instruction (Miltenyi 
Biotec). RNA was isolated using RNeasy Mini Kit (Qiagen) and transcribed with iScript cDNA Synthesis Kit 
(BioRad). RT-PCR was performed with SsoFast EvaGreen Supermix (BioRad) and template-free negative controls 
were included. For the quantification of U6-gRNA(CD2.0) the total RNA of thymus and spleen was isolated using 
RNeasy Mini Kit (Qiagen) and reverse-transcribed with Moloney Murine Leukemia Virus Reverse Transcriptase 
RNase H− Point Mutant (Promega) according to the manufacturer’s instructions. RT-PCR was performed with 
KAPA SYBR FAST qPCR Universal Master Mix (Peqlab) and template-free and reverse transcriptase-free neg-
ative controls were included. Both transcript abundances were assessed using the Bio-Rad CFX384 systems and 
following primers were used: CD4-Cas9 F: 5′ -agc cct cat ata cac aca cct-3′ , CD4-Cas9 R: 5′ -acg ctg ttt gtg ccg 
ata-3′ ; CD4 F: 5′ - aga act ggt tcg gca tga ca-3′ , CD4 R: 5′ -aag gag aac tcc gct gac-3′ ; CD2 F: 5′ -ccc atg att cct tca tat 
ttg ca-3′ and CD2 R: 5′ -ggt cct tct cca gcc tag t-3′ ; Cxxc1 F: 5′ -ggt tgt tgc acg ggg tcc ag-3′ , Cxxc1 R: 5′ -ccc cat tct 
cag act tgc tgt cg-3′ ; Ywhaz F: 5′ -gtt act tgg ccg agg ttg ctg ct-3′ , Ywhaz R: 5′ -ggt gtg tcg gct gca tct cct t-3′ . Cxxc1 
and Ywhaz were used as reference genes. The Δ Δ Cq Analysis was performed with BioRad CFX Manager 3.1.
Flow cytometry. Blood samples and splenocytes were treated with red blood cell lysis buffer and along with 
lymph node cells and thymocytes were washed with phosphate buffered saline (PBS). They were stained in FACS 
buffer (PBS, 10% FCS, 0.01% NaN3) with anti-CD2 FITC, anti-TCRβ PE, anti-CD8 PerCP, anti-CD19 APC and 
anti-CD4 PB (all Biolegend). Live/Dead discrimination was performed by propidium iodide or Live Dead Fixable 
Aqua Dead Cell Stain Kit (Life Technologies). Single cells were sorted (BD, MoFlow) onto AmpliGrid slides and 
processed immediately. For FACS analysis, cells were acquired at BD Canto II and Aria 5. Analysis was performed 
with FlowJo 9.4 and 10.
Molecular Biology. Single cell PCR was performed as a nested PCR. The outer PCR was performed with 
Advantage2 (Clontech) directly on the AmpliGrid slide. For the inner PCR, Herculase II Fusion Enzyme with 
dNTP combos (Agilent) was used. PCRs were performed with the following primers: out fwd: 5′ -atc acc ctg aac 
atc ccc aac-3′ , out rev: 5′ -act gga gtc ttc tt gtg ggc-3′ (product length: 382bp); in fwd: 5′ -ctg gtc gca gag ttt aaa 
agg-3′ , in rev: 5′ -gct gct ccc caa ctt tct ac-3′ (product length 253bp). One AmpliGrid slide consists of 48 wells, of 
which every sixth sample was not loaded with a cell and served as negative control.
The Cas9-gRNA efficiency test of four different gRNAs targeting CD2 was performed in vitro on 
column-purified 839 bp CD2 PCR products (Wizard SV Gel and PCR Clean-UP System, Promega) which were 
amplified using Taq PCR Master Mix Kit (Qiagen) and following primers: CD2 cut F: 5′ -cct gac aga aag aac 
tc-3′ , CD2 cut R: 5′ -ctc act gct cct agg ca-3′ . Either PCR product or annealed oligos (PCR primer: T7 CD2.0 F: 
5′ -taa tac gac tca cta tag ggg act agg ctg gag aag gac c-3′ , T7 CD2.0 R: 5′ -gca gcg gct aaa aac gga-3′ ; oligos: T7 
promoter F: 5′ -taa tac gac tca cta tag gg-3′ , CD2.1 R: 5′ -aaa agc acc gac tcg gtg cca ctt ttt caa gtt gat aac gga cta 
gcc tta ttt taa ctt gct att tct agc tct aaa aca aga cac ccc aga tgg tct ccc cta tag tga gtc gta tta-3′ , CD2.2 R: 5′ -aaa agc 
acc gac tcg gtg cca ctt ttt caa gtt gat aac gga cta gcc tta ttt taa ctt gct att tct agc tct aaa acg aac atc ccc aac ttt caa 
acc cta tag tga gtc gta tta-3′ , CD2.3 R: 5′ - aaa agc acc gac tcg gtg cca ctt ttt caa gtt gat aac gga cta gcc tta ttt taa 
ctt gct att tct agc tct aaa act cgc acc tca tca ata tca tcc cta tag tga gtc gta tta-3′ ) were used to transcribe RNA with 
MEGAshortscript T7 Transcription Kit (ThermoFisher Scientific) and purified with MEGAclear Transcription 
Clean-Up Kit (ThermoFisher Scientific). gRNA and Cas9 Nuclease, S pyogenes (NEB) were preincubated for 
10 min at room temperature. After adding the CD2 PCR product the mix was incubated for either 1 h or 1.5 h at 
37 °C and finally analyzed on an agarose gel. The following fragment sizes are expected: gRNA(CD2.0): 499 bp 
and 340 bp, gRNA(CD2.1): 251 bp and 588 bp, gRNA(CD2.2): 269 bp and 570 bp, gRNA(CD2.3): 312 bp and 527 
bp. The signal quantification was performed using ImageJ 1.50a.
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